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Salmonella enterica serotype Typhi is endemic in
developing countries in Africa, South and Central America,
and the Indian subcontinent, with an estimated incidence of
33 million cases each year (1). By contrast, in developed
countries such as the United Kingdom or the USA, incidence
is much lower, and most cases are in travelers returning from
endemic areas. For example, 150 to 300 cases occur each year
in the U.K., at least 70% in patients with a history of recent
foreign travel.
For patients with typhoid fever, administration of an
effective antibiotic should begin as soon as clinical diagnosis
is made, without recourse to results of antimicrobial
sensitivity tests. From 1948 to the mid-1970s, chlorampheni-
col was the first-line drug of choice, and in developed countries
its use resulted in a reduction in mortality rates from 10% to
<2%. After extensive outbreaks of typhoid fever occurred in
Mexico and India in the early and mid-1970s, in which
epidemic strains were resistant to chloramphenicol (2,3), the
efficacy of this antimicrobial agent was in doubt.
Alternative drugs for typhoid fever are ampicillin and
trimethoprim. However, following outbreaks in the Indian
subcontinent, the Arabian Gulf, the Philippines, and South
Africa in the late 1980s and early 1990s, in which causative
strains were resistant to ampicillin and trimethoprim in
addition to chloramphenicol, the efficacy of these antimicrobi-
al agents has also been impaired (4).
The Laboratory of Enteric Pathogens of the Public Health
Laboratory Service of England and Wales is the reference
center in the U.K. for strains of S. Typhi. Strains are
identified by Vi-phage typing; all strains are tested with an
agar dilution method for resistance to a panel of antimicrobial
drugs. The final plate concentrations for selected antimicrobi-
al drugs were chloramphenicol 8 mg/L, ampicillin 8 mg/L,
trimethoprim 2 mg/L, nalidixic acid 16 mg/L, ciprofloxacin
0.125 mg/L, ceftriaxone 1 mg/L, and cefotaxime 1 mg/L.
For isolates resistant to ciprofloxacin at 0.125 mg/L, full
MICs are determined either by incorporating doubled
concentrations of the antimicrobial agent into the agar
substrate or by E-test. All isolates resistant to ciprofloxacin at
0.125 mg/L were also resistant to nalidixic acid at 16 mg/L. In
contrast, isolates sensitive to nalidixic acid at 16 mg/L had
MICs to ciprofloxacin of <0.025 mg/L. All strains with
resistance to chloramphenicol, ampicillin, trimethoprim, or
nalidixic acid/ciprofloxacin were tested for the ability to
transfer these resistances to a drug-sensitive strain of
Escherichia coli K12. Resultant resistance plasmids were
characterized by incompatibility grouping and agarose gel
electrophoresis after extraction of plasmid DNA from donor
strains of S. Typhi and recipient strains of E. coli K12.
From 1978 to 1985, resistance to chloramphenicol was
identified in 11 (0.47%) of 2,356 strains studied (5); therefore,
chloramphenicol remained the first-line drug for typhoid
fever before results of laboratory sensitivity tests became
available. From 1986 to 1989, chloramphenicol resistance
increased threefold: 12 (1.5%) of 790 isolates were resistant.
However, this increase was not considered sufficient to
change recommendations about therapy. In 1990, there was a
dramatic change, with 20% of 248 isolates resistant to
chloramphenicol; most were also resistant to ampicillin and
trimethoprim (6). In 1991, because of this increased
chloramphenicol resistance, ciprofloxacin was recommended
as an alternative for patients with a history of recent travel to
epidemic areas (7).
From 1990 to 1999, 151 to 291 (mean 210) patients per
year in the U.K. had typhoid fever. The incidence of multidrug
resistance (MDR) to chloramphenicol, ampicillin, and
trimethoprim increased from 21% in 1991 to 36% in 1994,
declined to 13% in 1997, and then increased to 26% in 1999
(Table 1). More than 90% of patients infected with MDR
strains had recently returned from the Indian subcontinent,
particularly Pakistan and India. The reasons for the decline
in MDR strains in 1997 followed by the return to 1996 levels
in 1998 and 1999 are not known but may be related to changes
in climatic conditions in the Indian subcontinent in the mid-
1990s, followed by reestablishment of MDR strains in
different parts of India in the late 1990s. Epidemiologic
investigations to test these hypotheses are in progress.
In the early 1990s, the most common Vi-phage type in
MDR strains was phage type M1, and almost all patients
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infected with strains of this phage type had acquired the
infections in Pakistan. The last isolations of MDR phage type
M1 in the U.K. were in 1994 (4). Since 1993, the most common
MDR phage type has been E1. Most patients infected with
MDR strains of phage type E1 had acquired the infections in
India or Pakistan. However, infections were also recorded in
patients returning from Bangladesh, Sri Lanka, and
Afghanistan. Regardless of phage type, in all MDR strains
resistance to chloramphenicol, ampicillin, and trimethoprim
has been encoded by plasmids of approximately 100
megadaltons belonging to the H1 incompatibility group.
In 1991, a strain of S.  Typhi with plasmid-encoded
resistance to chloramphenicol, ampicillin, and trimethoprim
and with chromosomally encoded resistance to nalidixic acid
(MIC 512 mg/L) was isolated from a 1-year-old child who had
recently returned from India. The strain also showed a
marked decrease in sensitivity to ciprofloxacin (MIC 0.6 mg/L).
The patient did not respond to treatment with ciprofloxacin
despite serum levels of 1.5 mg/L. In 1995, 8 (3%) of 291
isolates showed decreased sensitivity to ciprofloxacin (MICs
0.38–0.75 mg/L by E-test); 5 were also resistant to
chloramphenicol, ampicillin, and trimethoprim. In 1998, 32
(21%) of 151 strains exhibited decreased susceptibility to
ciprofloxacin. One patient, a 65-year-old woman who returned
from India infected with a strain of phage type E1 (MIC to
ciprofloxacin of 1.0 mg/L) did not respond to twice a day
treatment with ciprofloxacin, 400 mg intravenously. After 5
days, treatment was changed to amoxicillin and ceftriaxone.
Within 3 days, the patient’s condition improved, and after a
further 5 days she was apyrexial (8).
S. Typhi with decreased susceptibility to ciprofloxacin
increased to 23% in the U.K. in 1999 (Table 1). All strains with
decreased sensitivity to ciprofloxacin were also resistant to
nalidixic acid (MIC 512 mg/L). The predominant phage types
have been E1 (81% of cases) and E9 (4%). However, strains of
phage types C2, E7, M1, untypeable Vi (UVS), and Vi-
negative have also been identified. Most patients had recently
returned from India or Pakistan. However, in 1998 and 1999,
strains with decreased susceptibility to ciprofloxacin were
also isolated from travelers returning from Sri Lanka, Nepal,
Bangladesh, and Thailand (Table 2). Furthermore, in both
years >50% of isolates with decreased susceptibility to
ciprofloxacin were also MDR (Table 1). In 1999, at least 10
patients infected with strains with decreased susceptibility to
ciprofloxacin did not respond to treatment with fluoroquinolone
antimicrobials. In such cases, ceftriaxone was the most
frequently used alternative. In contrast to resistance to
chloramphenicol, ampicillin, and trimethoprim, resistance to
ciprofloxacin has been chromosomally encoded in all isolates
with decreased sensitivity to this antimicrobial agent.
Since 1993, strains of S.  Typhi with decreased
susceptibility to ciprofloxacin have been isolated with
increasing frequency in Vietnam (9). In 1997, >6,000 cases
occurred in an extensive epidemic in Tajikistan of nalidixic
acid-resistant  S. Typhi with decreased susceptibility to
ciprofloxacin (10). The epidemic strain was untypeable with
the Vi typing phages but had a pulsed-field profile
indistinguishable from that of isolates of MDR Vi-phage type
E1 from patients infected in India (11). In both Vietnam and
Tajikistan, treatment failures with fluoroquinolone antibiot-
ics have been noted.
The accepted British Society for Antimicrobial Chemo-
therapy and National Committee for Clinical Laboratory
Standards’ zone size equivalents for resistance to ciprofloxa-
cin in disc diffusion tests are 2 mg/L and 4 mg/L, respectively,
for Enterobacteriaceae. However, testing for resistance at
these levels could result in decreased susceptibilities not
being detected. As all strains with decreased susceptibility to
ciprofloxacin have also been resistant to nalidixic acid, we
suggest that the latter antimicrobial agent be included in the
panel of drugs used for sensitivity testing. If resistance to
nalidixic acid is detected, full MICs to ciprofloxacin should be
performed in the event of treatment failure.
Table 2. Phage types in Salmonella Typhi isolates with decreased susceptibility to ciprofloxacin (CpL), United Kingdom, 1991–1999
Phage types
Year CpL E1 M1 E9 Others Country of origin (no.)
1991   2   2 0 0 0 India (1), Nepal (1)
1992   1   0 0 0 1 (B2) India (1)
1993   1   0 0 0 1 (E14) Bangladesh (1)
1994   5   5 0 0 0 India (3), Nepal (1), Bangladesh (1)
1995   8   6 1 0 1 (D1) India (4), Pakistan (3), NSa (1)
1996 11 11 0 0 0 India (9), Pakistan (2)
1997   9   8 0 0 1(A) India (5), Pakistan (2), Nepal (1), NS (1)
1998 32 23 0 6 3 (G2,2;O,1) Pakistan (14), India (9), Sri Lanka (1), Bangladesh (1), NS (7)
1999 42 27 1 3 11 (UVS, 7; E7, 1; C2, 1; India (31), Pakistan (6), Bangladesh (1), Thailand (1), NS (3)
  Vi-negative, 1)
aNS = details of travel itinerary not provided; UVS = untypeable with the Vi typing phages.
Table 1. Incidence of multidrug resistance and decreased susceptibility
to ciprofloxacin in Salmonella enterica serotype Typhi, U.K., 1990–1999
 Decreased
   suscepti-             CPL strains
    MDRb   bility to CPL also resistant to:
Year Strainsa  no. (%)  no. (%)  C  A Tm Ct Cf
1990 248   50 (20)   0 (0)   0   0   0 0 0
1991 226   48 (21)   2 (0.9)   1   1   1 0 0
1992 204   49 (24)   1 (0.5)   0   0   0 0 0
1993 194   49 (25)   1 (0.5)   1   1   1 0 0
1994 259   94 (36)   5 (2)   5   5   5 0 0
1995 291 100 (34)   8 (3)   5   5   5 0 0
1996 210   52 (25) 11 (7)   7   7   7 0 0
1997 174   22 (13)   9 (5)   6   6   6 0 0
1998 151   34 (23) 32 (21) 19 19 19 0 0
1999 179   47 (26) 42 (23) 25 25 25 0 0
aStrains referred to Laboratory of Enteric Pathogens.
bMDR = multidrug resistant (to chloramphenicol, ampicillin, and trimethoprim).
Resistance symbols: C, chloramphenicol; A, ampicillin; Tm, trimethoprim;
CPL, ciprofloxacin (MIC 0.25-1.0 mg/L); Ct, ceftriaxone; Cf, cefotaxime.
Percentages of total isolates in parentheses.Dispatches
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Our findings suggest that strains of S.  Typhi with
decreased sensitivity to ciprofloxacin are now endemic in
several countries in the Indian subcontinent and that such
strains are increasing in travelers returning to the U.K.
Despite the low level of resistance, treatment failures are
being increasingly noted. In such cases, possible alternatives
such as ceftriaxone or cefotaxime could be considered. In this
respect, it is reassuring that all strains of S. Typhi so far
tested were sensitive to these antimicrobial drugs.
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References
  1. Ivanoff B. Typhoid fever: global situation and WHO recommendations.
Southeast Asian J Trop Med Public Health 1995; 26(Suppl 2):1-6.
    2. Anderson ES, Smith HR. Chloramphenicol resistance in the
typhoid bacillus. BMJ 1972;3:329-31.
  3. Paniker CKJ, Vilma KN. Transferable chloramphenicol resistance
in Salmonella typhi. Nature 1972;239:109-10.
  4. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi:
a worldwide epidemic. Clin Infect Dis 1997;24(Suppl 1): S106-9.
  5. Rowe B, Threlfall EJ, Ward LR. Does chloramphenicol remain the
drug of choice for typhoid? Epidemiol Infect 1987;98:379-83.
    6. Rowe B, Ward LR, Threlfall EJ. Spread of multiresistant
Salmonella typhi. Lancet 1990;336:1065-6.
    7. Rowe B, Ward LR, Threlfall EJ. Treatment of multiresistant
typhoid fever. Lancet 1991;337:1422.
    8. Threlfall EJ, Ward LR, Skinner JA, Smith HR, Lacey S.
Ciprofloxacin-resistant Salmonella typhi and treatment failure.
Lancet 1999;353:1590-1.
    9. Parry C, Wain J, Chinh NT, Vinh Ha, Farrar JJ. Quinolone-
resistant Salmonella typhi in Vietnam. Lancet 1998;351:1289.
10. Murdoch DA, Banatvala NA, Bone A, Shoismatulloev BI, Ward LR,
Threlfall EJ, et al. Epidemic ciprofloxacin-resistant Salmonella
typhi in Tajikistan. Lancet 1998;351:339.
11. Hampton MD, Ward LR, Rowe B, Threlfall EJ. Molecular
fingerprinting of multidrug-resistant Salmonella enterica serotype
Typhi. Emerg Infect Dis 1998;4:317-20.